Precigen to Participate in the JMP Securities Hematology and Oncology Summit
GERMANTOWN, Md., Nov. 29, 2023 /PRNewswire/ — Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on Wednesday, December 6, 2023 at 3:00 PM ET.
Related news for (PGEN)
- Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis
- Precigen Announces Up to $125 Million Non-Dilutive Financing
- Biotech Rally Builds as Markets Eye Buybacks and Breakouts
- Biotech Closing Strong, Set for After-Hours Surprises as Momentum Builds
- Don’t Miss Out: MoBot’s Latest Stock Updates 08/21/25 10:00 AM
